RxDoctor Payments Data

Richard Hammoud, MD

Internal Medicine · Dearborn, MINPI 1255330767

Payments from drug & device makers

$3,419in general payments, 2019–2025

Across 128 payments — averaging $26.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cequr Corporation$1K
  • GSK$807
  • AstraZeneca$447
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$236
  • AbbVie$140
  • Boehringer Ingelheim$135
  • plus $314 from 4 others

What the payments were for

  • Food & beverage$3,419100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,419 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$115,757
Medicare patients
231
Services billed
1,635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban380$198,979
Trelegy ElliptaFluticasone/Umeclidin/Vilanter246$189,799
OzempicSemaglutide153$156,899
JardianceEmpagliflozin125$94,475
JanuviaSitagliptin Phosphate121$90,924
MounjaroTirzepatide60$61,377
TrulicityDulaglutide35$47,099
TradjentaLinagliptin63$45,265
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog118$43,766
EntrestoSacubitril/Valsartan46$38,669
LinzessLinaclotide61$38,412
Nurtec OdtRimegepant Sulfate19$31,769
BrilintaTicagrelor50$27,516
XareltoRivaroxaban35$27,318
Risperidone ErRisperidone Microspheres22$25,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$73$230,748399 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$807$225,172324 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$135$157,067219 claims
Lilly USA, LLCMounjaro, Trulicity$16$108,47695 claims
AstraZenecaBrilinta, Breztri Aerosphere, Farxiga$447$65,551101 claims
AbbVieLinzess, Vraylar$140$57,03874 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →